This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (120)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Women's Health  • Women's Health, Other  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

The Women's Health Initiative

Judith Hsia, MD; Robert D. Langer, MD, MPH; JoAnn E. Manson, MD, DrPH; Lewis Kuller, MD, DrPH; Karen C. Johnson, MD, MPH; Susan L. Hendrix, DO; Mary Pettinger, MS; Susan R. Heckbert, MD, PhD; Nancy Greep, MD; Sybil Crawford, PhD; Charles B. Eaton, MD; John B. Kostis, MD; Pat Caralis, MD; Ross Prentice, PhD; for the Women's Health Initiative Investigators

Arch Intern Med. 2006;166:357-365.

Background  In recent randomized trials, conjugated equine estrogens (CEE) with continuous medroxyprogesterone acetate provided no protection against coronary heart disease in postmenopausal women and may have increased cardiac risk. These trials did not address the role of unopposed estrogen for coronary protection.

Methods  A total of 10 739 women aged 50 to 79 years at baseline (mean age, 63.6 years) who had previously undergone hysterectomy were randomized to receive CEE, 0.625 mg/d, or placebo at 40 US clinical centers beginning in 1993. The trial was terminated early after 6.8 years of follow-up (planned duration, 8.5 years). This report includes final, centrally adjudicated results for the primary efficacy outcome (myocardial infarction or coronary death), secondary coronary outcomes, and subgroup analyses.

Results  During the active intervention period, 201 coronary events were confirmed among women assigned to receive CEE compared with 217 events among women assigned to receive placebo (hazard ratio, 0.95; nominal 95% confidence interval, 0.79-1.16). Among women aged 50 to 59 years at baseline, the hazard ratio for the primary outcome was 0.63 (nominal 95% confidence interval, 0.36-1.08). In that age group, coronary revascularization was less frequent among women assigned to receive CEE (hazard ratio, 0.55; nominal 95% confidence interval, 0.35-0.86), as were several composite outcomes, which included the primary outcome and coronary revascularization (hazard ratio, 0.66; nominal 95% confidence interval, 0.44-0.97).

Conclusions  Conjugated equine estrogens provided no overall protection against myocardial infarction or coronary death in generally healthy postmenopausal women during a 7-year period of use. There was a suggestion of lower coronary heart disease risk with CEE among women 50 to 59 years of age at baseline.

Author Affiliations: Department of Medicine, George Washington University, Washington, DC (Dr Hsia); Department of Family and Preventive Medicine, University of California at San Diego (Dr Langer); Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (Dr Manson); Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pa (Dr Kuller); Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis (Dr Johnson); Department of Obstetrics and Gynecology, Wayne State University/Hutzel Women's Hospital, Detroit, Mich (Dr Hendrix), Fred Hutchinson Cancer Research Center (Ms Pettinger and Dr Prentice) and Department of Epidemiology, University of Washington, Seattle (Dr Heckbert); Department of Obstetrics and Gynecology, University of California, Irvine (Dr Greep); Department of Medicine, University of Massachusetts Medical School, Worcester (Dr Crawford); Department of Family Medicine and Center for Primary Care and Prevention, Brown University School of Medicine and Memorial Hospital of Rhode Island, Pawtucket (Dr Eaton); Department of Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ (Dr Kostis); and University of Miami School of Medicine and Miami Veterans Administration Medical Center, Miami, Fla (Dr Caralis).
Group Information: A complete list of The Women's Health Initiative investigators appears in JAMA (2004;291:1701-1712).

RELATED LETTERS

Estrogen and Heart Disease: Alternatives to a Paradigm in Crisis
Jerome L. Sullivan
Arch Intern Med. 2006;166(19):2160.
EXTRACT | FULL TEXT  

Estrogen and Heart Disease: Alternatives to a Paradigm in Crisis—Reply
Judith Hsia, JoAnn E. Manson, Karen C. Johnson, Susan L. Hendrix, Susan R. Heckbert, Sybil Crawford, Charles B. Eaton, and John B. Kostis
Arch Intern Med. 2006;166(19):2160.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sex differences in vascular function: implication of endothelium-derived hyperpolarizing factor
Villar et al.
J Endocrinol 2008;197:447-462.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Therapy and Stroke: Role of Time Since Menopause and Age at Initiation of Hormone Therapy
Grodstein et al.
Arch Intern Med 2008;168:861-866.
ABSTRACT | FULL TEXT  

Medical Management of Small Abdominal Aortic Aneurysms
Baxter et al.
Circulation 2008;117:1883-1889.
ABSTRACT | FULL TEXT  

Sex Steroids and Renal Disease: Lessons From Animal Studies
Yanes et al.
Hypertension 2008;51:976-981.
FULL TEXT  

Primary prevention of coronary heart disease in women
Rees et al.
Menopause Int 2008;14:40-45.
ABSTRACT | FULL TEXT  

RE: "INVITED COMMENTARY: HORMONE THERAPY AND RISK OF CORONARY HEART DISEASE WHY RENEW THE FOCUS ON THE EARLY YEARS OF MENOPAUSE?"
Rosenberg
Am J Epidemiol 2007;166:1480-1481.
FULL TEXT  

New findings from non-linear longitudinal modelling of menopausal hormone changes
Dennerstein et al.
Hum Reprod Update 2007;13:551-557.
ABSTRACT | FULL TEXT  

Invited Commentary: Hormone Therapy and Risk of Coronary Heart Disease Why Renew the Focus on the Early Years of Menopause?
Manson and Bassuk
Am J Epidemiol 2007;166:511-517.
ABSTRACT | FULL TEXT  

Hormones and Heart Disease in Women: The Timing Hypothesis
Barrett-Connor
Am J Epidemiol 2007;166:506-510.
ABSTRACT | FULL TEXT  

Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists
Collins et al.
Eur Heart J 2007;28:2028-2040.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Atherosclerosis in Postmenopausal Women: Does Aging Limit Therapeutic Benefits?
Barton et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:1669-1672.
FULL TEXT  

Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors
Simoncini et al.
Hum Reprod 2007;22:2325-2334.
ABSTRACT | FULL TEXT  

Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women
Bansal et al.
JAMA 2007;298:309-316.
ABSTRACT | FULL TEXT  

Estrogen protects against the development of salt-induced cardiac hypertrophy in heterozygous proANP gene-disrupted mice
Sangaralingham et al.
J Endocrinol 2007;194:143-152.
ABSTRACT | FULL TEXT  

Estrogen Therapy and Coronary-Artery Calcification
Manson et al.
NEJM 2007;356:2591-2602.
ABSTRACT | FULL TEXT  

HRT and the Young at Heart
Mendelsohn and Karas
NEJM 2007;356:2639-2641.
FULL TEXT  

Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy
Tannen et al.
Hum Reprod 2007;22:1769-1777.
ABSTRACT | FULL TEXT  

Coadministration of Estradiol/Drospirenone and Indomethacin Does Not Cause Hyperkalemia in Healthy Postmenopausal Women: A Randomized Open-Label Crossover Study
Schutt et al.
J Clin Pharmacol 2007;47:774-781.
ABSTRACT | FULL TEXT  

Estrogen-TNF interactions and vascular inflammation
Ferreri
Am. J. Physiol. Heart Circ. Physiol. 2007;292:H2566-H2569.
FULL TEXT  

Sex Differences in Perceived Risks, Distrust, and Willingness to Participate in Clinical Trials: A Randomized Study of Cardiovascular Prevention Trials
Ding et al.
Arch Intern Med 2007;167:905-912.
ABSTRACT | FULL TEXT  

Review Article: Vascular and Metabolic Effects of Sex Steroids: New Insights Into Clinical Trials
Wierman and Kohrt
Reproductive Sciences 2007;14:300-314.
ABSTRACT  

Managing the menopause
Roberts
BMJ 2007;334:736-741.
FULL TEXT  

Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause
Rossouw et al.
JAMA 2007;297:1465-1477.
ABSTRACT | FULL TEXT  

The Effect of Menopause on the Metabolic Syndrome Among Korean Women: The Korean National Health and Nutrition Examination Survey, 2001
Kim et al.
Diabetes Care 2007;30:701-706.
ABSTRACT | FULL TEXT  

Unopposed Estradiol Therapy in Postmenopausal Women: Results From Two Randomized Trials
Steiner et al.
Obstet Gynecol 2007;109:581-587.
ABSTRACT | FULL TEXT  

Low Dose of Transdermal Estradiol Gel for Treatment of Symptomatic Postmenopausal Women: A Randomized Controlled Trial
Simon et al.
Obstet Gynecol 2007;109:588-596.
ABSTRACT | FULL TEXT  

Selective Activation of Estrogen Receptor-{beta} Transcriptional Pathways by an Herbal Extract
Cvoro et al.
Endocrinology 2007;148:538-547.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Cardioprotection: What Is Good and What Is Bad for the Cardiovascular System?
ROSANO et al.
Ann. N. Y. Acad. Sci. 2006;1092:341-348.
ABSTRACT | FULL TEXT  

Estrogen Receptor-Mediated Rapid Signaling
Moriarty et al.
Endocrinology 2006;147:5557-5563.
ABSTRACT | FULL TEXT  

Implications of Recent Clinical Trials of Postmenopausal Hormone Therapy for Management of Cardiovascular Disease
ROSSOUW
Ann. N. Y. Acad. Sci. 2006;1089:444-453.
ABSTRACT | FULL TEXT  

Obese women and the relation between cardiovascular risk profile and hormone therapy, glucose tolerance, and psychosocial conditions.
Lidfeldt et al.
Diabetes Care 2006;29:2477-2482.
ABSTRACT | FULL TEXT  

Effect of Conjugated Equine Estrogens on Oxidative Metabolism in Middle-aged and Elderly Postmenopausal Women.
O'Connell et al.
J Clin Pharmacol 2006;46:1299-1307.
ABSTRACT | FULL TEXT  

Estrogen and heart disease: alternatives to a paradigm in crisis.
Sullivan
Arch Intern Med 2006;166:2160-2160.
FULL TEXT  

Estrogen and Heart Disease: Alternatives to a Paradigm in Crisis--Reply
Hsia et al.
Arch Intern Med 2006;166:2160-2160.
FULL TEXT  

Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate.
Simoncini et al.
Obstet Gynecol 2006;108:969-978.
ABSTRACT | FULL TEXT  

Selective Agonists of Estrogen Receptor Isoforms: New Perspectives for Cardiovascular Disease
Bolego et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:2192-2199.
ABSTRACT | FULL TEXT  

Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study
Collins et al.
Eur Heart J 2006;27:2046-2053.
ABSTRACT | FULL TEXT  

Cardiovascular Disease, Estrogen Deficiency, and Inflammatory Cytokines
Reckelhoff
Hypertension 2006;48:372-373.
FULL TEXT  

The women's health initiative--curse or blessing?
Michels
Int J Epidemiol 2006;35:814-816.
FULL TEXT  

Premature Ovarian Failure in Cancer Survivors: New Insights, Looming Concerns.
Chen and Manson
JNCI J Natl Cancer Inst 2006;98:880-881.
FULL TEXT  

FIVE AUTHORS REPLY
Prentice et al.
Am J Epidemiol 2006;163:1068-1069.
FULL TEXT  

WOMEN'S HEALTH INITIATIVE UPDATE: Estrogen and Coronary Heart Disease
JWatch Women's Health 2006;2006:2-2.
FULL TEXT  

Lingering Questions About Hormone Therapy
JWatch General 2006;2006:5-5.
FULL TEXT  

Lingering Questions About Hormone Therapy
Journal Watch Cardiology 2006;2006:1-1.
FULL TEXT